ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer's Disease - Seite 3

For further information please consult the Company's website at:
www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

For media inquiries, please contact:

Scott Santiamo
RussoPartners/LLC
[e-mail]
Office: [phone]
Mobile: [phone]

[e-mail]

or contact

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. [phone]
[e-mail]

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via Globenewswire